OverviewSuggest Edit

Tempus is a technology company that is building the world’s largest library of molecular and clinical data and an operating system to make that data accessible and useful. It enables physicians to deliver personalized cancer care for patients through interactive analytical and machine learning platform. Tempus provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. The Company's goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as Tempus gathers more data. 
TypePrivate
Founded2015
HQChicago, US
Websitetempus.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Dec 2019)757(+4%)
Job Openings111

Key People/Management at Tempus

Eric Lefkofsky

Eric Lefkofsky

Co-Founder and CEO
Kevin White

Kevin White

President
Gary Palmer

Gary Palmer

Chief Medical Officer
Nike Beaubier

Nike Beaubier

Director of Pathology and Medical Lab Operations
Erik Phelps

Erik Phelps

Executive Vice President and General Counsel
Shane Colley

Shane Colley

Senior Vice President of Engineering
Show more

Tempus Office Locations

Tempus has an office in Chicago
Chicago, US (HQ)
600 W Chicago Ave #775
Show all (1)

Tempus Financials and Metrics

Summary Metrics

Founding Date

2015

Tempus total Funding

$520 m

Tempus latest funding size

$200 m

Time since last funding

6 months ago

Tempus investors

Tempus's latest funding round in May 2019 was reported to be $200 m. In total, Tempus has raised $520 m. Tempus's latest valuation is reported to be $3.1 b.
View all funding rounds

Tempus Revenue

Market valuation

3.1b
Show all financial metrics

Tempus Online and Social Media Presence

Embed Graph

Tempus News and Updates

Tempus Resource Delivers the Future in PPM at PMO Symposium 2019

Industry expert to lead discussion on best practices for the future of resource portfolio management

Tempus Resource Launches Exclusive Video Series With Donna Fitzgerald

Resource management and PPM industry expert partners with leading technology company to produce thought leadership videos

TangoTrade enlists Tempus for payment assurance

TangoTrade, a financial software provider that empowers small and medium-sized businesses (SMBs) to...

Tempus Resource to Present Its Revolutionary Audit Resource Management Tool

Company founder and industry expert Sean Pales will demonstrate how Tempus Resource transforms audit resource forecasting and capacity planning

Tempus Resource Answers the Question, "How Can an Organization Be Successful in the Digital Future?" at Gartner PPM in D.C.

Accomplished industry professional Donna Fitzgerald to speak on resource capacity planning at the Gartner Program & Portfolio Management Summit

Tempus Resource Answers the Question 'How Can an Organization Be Successful in the Digital Future?'

Accomplished industry professional Donna Fitzgerald to speak on resource capacity planning at Gartner Portfolio Management Summit
Show more

Tempus Blogs

Eric Lefkofsky as Keynote Speaker of Cleveland Clinic’s 2019 Medical Innovation Summit

Eric Lefkofsky and Tom Mihaljevic discuss Tempus and the future of precision medicine. Video linked here.     The post Eric Lefkofsky as Keynote Speaker of Cleveland Clinic’s 2019 Medical Innovation Summit appeared first on Tempus.

Microsatellite Instability Detection with Cell-free DNA Next-generation Sequencing

Society for Immunotherapy of Cancer 2019, Tempus-authored – Microsatellite instability is a clinically actionable genomic indication for cancer immunotherapy. In microsatellite instability-high (MSI-H) tumors, defects in DNA mismatch repair (MMR) can cause a hypermutated phenotype where alterations …

Detection of Human Leukocyte Antigen Class I Loss of Heterozygosity in Solid Tumor Types by Next-generation DNA Sequencing

Society for Immunotherapy of Cancer 2019, Tempus-authored — Human leukocyte antigen (HLA) class I proteins are expressed on the surface of all nucleated cells and are vital for immune surveillance. When tumor-specific mutations (neoantigens) are presented on HLA molecules to CD8+ T cells, this recog…

Presence of Chip-Mutated Autologous Hematopoietic Cells in Mobilized Peripheral Blood Products Is Associated with Shorter Progression-Free Survival after Autologous Transplants for Multiple Myeloma

American Society of Hematology 2019, Tempus-authored — Multiple Myeloma (MM) remains a cancer of terminally-differentiated plasma cells that reside predominantly within the bone marrow. Malignant plasma cells are nurtured by a permissive microenvironment that favors tumor progression, drug resistanc…

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board Of Directors

Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging hi…

Integrated Genomic Profiling Expands Clinical Options for Patients with Cancer

Nature Biotechnology, Tempus-authored – Genomic analysis of paired tumor–normal samples and clinical data can be used to match patients to cancer therapies or clinical trials. We analyzed 500 patient samples across diverse tumor types using the Tempus xT platform by DNA-seq, RNA-seq and immunologica…
Show more

Tempus Frequently Asked Questions

  • When was Tempus founded?

    Tempus was founded in 2015.

  • Who are Tempus key executives?

    Tempus's key executives are Eric Lefkofsky, Kevin White and Gary Palmer.

  • How many employees does Tempus have?

    Tempus has 757 employees.

  • Who are Tempus competitors?

    Competitors of Tempus include MedWhat, PeraHealth and Treato.

  • Where is Tempus headquarters?

    Tempus headquarters is located at 600 W Chicago Ave #775, Chicago.

  • Where are Tempus offices?

    Tempus has an office in Chicago.

  • How many offices does Tempus have?

    Tempus has 1 office.